Welcome to our dedicated page for Revvity SEC filings (Ticker: RVTY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Revvity, Inc.'s SEC filings document operating results, governance matters and capital-structure disclosures for a Massachusetts-incorporated life sciences and diagnostics company. Its 8-K reports furnish quarterly and annual financial results, preliminary performance updates, Regulation FD investor presentation materials and other material-event disclosures.
Proxy and annual-meeting filings describe director elections, auditor ratification, advisory executive-compensation votes and shareholder-approved bylaw amendments, including the ability of holders of 25% of the company's stock to call a special meeting. Other current reports identify registered securities, including RVTY common stock and 1.875% notes due 2026 listed on the New York Stock Exchange, as well as officer appointments and related governance changes.
REVVITY, INC. officer Anita Gonzales reported equity compensation awards. On March 6, 2026, she received a grant of 1,616 nonqualified stock options for common stock at an exercise price of $93.07 per share, expiring on March 6, 2033.
On the same date she was also awarded 1,721 time-based restricted stock units, increasing her direct common stock holdings to 5,799 shares after the award. Both the options and RSUs are scheduled to vest in three equal installments on February 15, 2027, February 15, 2028, and February 15, 2029. These are compensation-related grants, not open-market purchases or sales.
Revvity, Inc. will hold its 2026 annual meeting virtually on April 28, 2026 with a record date of March 2, 2026. The board asks shareholders to elect ten directors for one-year terms and to vote on four additional proposals, including ratification of Deloitte & Touche LLP as auditor and a bylaw amendment to permit shareholders owning 25% to call a special meeting.
The company reported 111,803,327 shares outstanding as of the record date. The board recommends FOR Proposals 1–4 and AGAINST the shareholder proposal on executive stock ownership (Proposal 5). Director compensation and annual equity grants for non-employee directors are described, and institutional holders and beneficial ownership schedules are included.
Revvity, Inc. executive Victor Miriame reported option exercises and related share sales. On February 24, 2026, he exercised a nonqualified stock option for 1,862 shares of common stock through a derivative exercise at an exercise price of $0.00 per share.
He simultaneously acquired 1,862 shares of Revvity common stock at $95.74 per share through this option exercise and then sold 1,862 shares in an open-market transaction at $97.13 per share. After these transactions, he directly owned 18,122 shares of common stock. The sales were made under a Rule 10b5-1 trading plan adopted on November 26, 2025.
REVVITY, INC. director Michelle McMurry-Heath sold 600 shares of common stock in an open-market transaction. The weighted average sale price was $97.26 per share, with individual trades between $97.15 and $97.35. After this sale, she directly holds 4,233 shares.
Revvity, Inc. files its annual report describing a global health science business focused on Life Sciences and Diagnostics. The company provides reagents, instruments, software and services that support drug discovery, genomics, imaging and diagnostic testing, marketing products in more than 160 countries.
Revvity reports approximately 11,000 employees as of December 28, 2025 and around 2,000 sales and service representatives across about 40 countries. Its strategy emphasizes innovation, AI-enabled solutions, strategic acquisitions, disciplined capital allocation and operational excellence, while highlighting extensive regulatory, economic, supply chain, technology, environmental, data privacy and debt‑related risks.
Revvity, Inc. executive reports tax-related share disposition. Victor Miriame surrendered 1,031 shares of common stock at $96.03 per share to cover tax withholding triggered by the vesting of restricted stock granted on February 16, 2023.
After this tax-withholding disposition, Miriame directly holds 18,122 shares of Revvity common stock. The transaction reflects a required withholding under his restricted stock agreement rather than an open-market sale.
Revvity, Inc. officer Tajinder S. Vohra reported a tax-related share disposition. On this Form 4, Vohra surrendered 566 shares of common stock at $96.03 per share to satisfy tax withholding triggered by the vesting of restricted stock granted on February 16, 2023.
These shares were not sold in the open market but withheld as required under the Restricted Stock Agreement. After this tax-withholding disposition, Vohra directly holds 13,965 shares of Revvity common stock.
REVVITY, INC. officer Anita Gonzales reported tax-withholding dispositions of 237 shares of common stock on February 17, 2026 at $96.03 per share. The shares were surrendered to cover tax obligations triggered by vesting of restricted stock units granted in 2023, 2024, and 2025, and were not open-market sales. Following these transactions, she directly owned 4,078 common shares.